Acacia Pharma Group plc announced that its Marketing Authorization Application (MAA) for BARHEMSYS® (amisulpride injection) has been submitted, validated and is now under formal review in major European markets. The review process is expected to be completed by Q3/2022. BARHEMSYS was approved in February 2020 by the Food and Drug Administration (FDA) for use in the United States to prevent and treat postoperative nausea & vomiting (PONV) and became commercially available in August 2020. The MAA submission includes data from four positive Phase 3 studies investigating BARHEMSYS, including the first ever randomized, controlled trial to show successful treatment of active PONV in patients who have failed prior prophylaxis. More than 3,300 surgical patients and healthy volunteers were enrolled in the BARHEMSYS clinical development program.